Tenaya Therapeutics, Inc.
NASDAQ:TNYABiotechnology
-$0.00 today
- Market cap
- $69.95M
- Beta
- 2.82
- P/E (TTM)
- -1.3
- EPS (TTM)
- -$0.54
Volume 2.77M
Average 3.79M
TNYA Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
Tenaya Therapeutics, Inc.NASDAQ: TNYA
Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026
Selling, general & admin declines year over year
Q1 FY2026 selling, general & admin of $5.45M fell 15.7% year over year, behind the -4.5% change in trailing-twelve-month selling, general & admin. Sequentially, it fell 8.9% from the prior quarter. Over 3 fiscal years it compounded at +3.4% a year.
Context
- Selling, general & admin increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether selling, general & admin reaches the consensus estimate from 4 analysts of $0 (-100.0%) for the fiscal year ending Dec 2026, a slowdown from the +19.2% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $5.45M-8.9% QoQ
- Last fiscal yearDec 2025
- $24.72M+19.2% YoY
- LTMMar 2026
- $23.71M-4.5% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -15.7% | -100.0% | -84.3 pp |
| 1 year | +19.2% | -100.0% | -119.2 pp |
| 3-year CAGR | +3.4% | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Selling, General & Admin history
USD · from the income statement
- Latest · FY2025
- 24.72M USD
- Year-over-year change
- +19.2%
- 4-year CAGR
- +14.5%
| Period | Period end | Selling, General & Admin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 24.72M | +19.2% |
| FY2024 | 2024-12-31 | 20.74M | -15.2% |
| FY2023 | 2023-12-31 | 24.47M | +9.4% |
| FY2022 | 2022-12-31 | 22.37M | +55.5% |
| FY2021 | 2021-12-31 | 14.39M | — |
Selling, General & Admin vs competitors
How TNYA compares with its peers on the latest reported figures
- TNYA's LTM Mar 2026 selling, general & admin of $23.71M is the 8th highest of the 11 companies compared; the peer median is $31.74M.
- Its year-over-year change of -4.5% is the 7th highest of 11, against a peer median of -2.9%.
- Selling, general & admin amounts to 10537.3% of revenue for TNYA, versus a peer median of 136.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $4.7B | +29505.3% | +3.5% | — | |
| LTM Mar 2026 | $73.88M | +132.8% | +55.6% | 508.1% | |
| LTM Mar 2026 | $38.28M | -25.4% | -1.1% | 55.3% | |
| LTM Mar 2026 | $36.25M | -1.5% | -0.1% | 323.5% | |
| LTM Mar 2026 | $36.17M | -2.1% | +6.6% | 99.1% | |
| LTM Mar 2026 | $27.31M | -10.2% | +10.9% | 1354.8% | |
| LTM Mar 2026 | $26.89M | -3.6% | -3.6% | 95.3% | |
| LTM Mar 2026 | $23.71M | -4.5% | +3.4% | 10537.3% | |
| LTM Mar 2026 | $23.69M | +2.7% | +2.7% | — | |
| LTM Mar 2026 | $21.38M | -22.5% | -9.9% | 127.9% | |
| LTM Mar 2026 | $20.02M | -13.1% | -15.9% | 144.4% | |
| Peer median (excluding TNYA) | $31.74M | -2.9% | +1.3% | 136.2% | |
Competitors are the stored peer set for TNYA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 4.03M | 8.71M | 8.69M | 8.47M | 8.44M |
| Gross Profit | (4.03M) | (8.71M) | (8.69M) | (8.47M) | (8.44M) |
| Gross Margin | — | — | — | — | — |
| Research & Development | 54.39M | 94.54M | 98.04M | 86.74M | 68.61M |
| Selling, General & Admin | 14.39M | 22.37M | 24.47M | 20.74M | 24.72M |
| Operating Expenses | 68.78M | 116.91M | 122.51M | 107.48M | 84.9M |
| Depreciation & Amortization | 4.03M | 8.71M | 8.69M | 8.47M | 8.44M |
| EBITDA | (68.7M) | (114.95M) | (115.4M) | (102.66M) | (82.16M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (72.81M) | (125.62M) | (131.19M) | (115.95M) | (93.33M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 108K | 1.95M | 7.06M | 4.74M | 2.68M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 85K | 1.96M | 7.11M | 4.82M | 2.73M |
| Income Before Tax | (72.72M) | (123.67M) | (124.08M) | (111.13M) | (90.6M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (72.72M) | (123.67M) | (124.08M) | (111.13M) | (90.6M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (1.69) | (2.76) | (1.68) | (1.31) | (0.59) |
| EPS (Diluted) | (1.69) | (2.76) | (1.68) | (1.31) | (0.59) |
| Weighted Avg Shares | 41.29M | 44.82M | 73.79M | 84.82M | 152.97M |
| Weighted Avg Shares (Diluted) | 41.29M | 44.82M | 73.79M | 84.82M | 152.97M |
Tenaya Therapeutics, Inc.
NASDAQ:TNYA
Intrinsic Alpha fair value
Locked
Current Price
$0.31
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.